€72.30
1.97%
Borsa Italiana, Sep 25, 01:18 pm CEST. Market open.
ISIN
IT0005274094
Symbol
PHN

Pharmanutra Stock price

€70.90
-11.30 13.75% 1M
-4.90 6.46% 6M
+16.60 30.57% YTD
+30.05 73.56% 1Y
+20.00 39.29% 3Y
+4.30 6.46% 5Y
+56.97 409.13% 10Y
+56.97 409.13% 20Y
Borsa Italiana, Closing price Thu, Sep 24 2026
-0.10 0.14%
ISIN
IT0005274094
Symbol
PHN

Is Pharmanutra a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
€687.4m
Enterprise Value
€677.4m
Net debt
positive
Cash
€29.0m
Shares outstanding
9.6m
Valuation (TTM | estimate)
P/E
24.0
P/S
3.5 | 4.4
EV/Sales
3.4 | 4.3
EV/FCF
42.3
P/B
9.2
Dividends
DPS
€1.20
Yield 1Y | 5Y
1.7% | 1.5%
Growth 1Y | 5Y
20.0% | 12.4%
Payout 1Y | 3Y
47.9% | 51.5%
Increased
9 Years
Financials (TTM | estimate)
Revenue
€197.1m | €156.2m
EBITDA
€48.3m
EBIT
€43.3m
Net Income
€28.3m
Free Cash Flow
€16.0m
Growth (TTM | estimate)
Revenue
16.5% | 18.6%
EBITDA
11.7%
EBIT
12.7%
Net Income
21.3%
Free Cash Flow
-22.6%
Margin
Gross
96.1%
EBITDA
24.5%
EBIT
21.9%
Net
14.4%
Free Cash Flow
8.1%
Financial Health
Equity Ratio
57.0%
Return on Equity
28.0%
ROCE
44.7%
ROIC
39.1%
Debt/Equity
0.3
More
EPS
€3.0
FCF per Share
€1.7
Short interest
-
Employees
128
Rev per Employee
€1.0m

Pharmanutra Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pharmanutra forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pharmanutra forecast:

Buy
86%
Hold
14%

Financial data from Pharmanutra

Mar '26
+/-
%
197 197
16% 16%
100%
- Direct Costs 7.61 7.61
1% 1%
4%
190 190
17% 17%
96%
- Selling and Administrative Expenses 140 140
21% 21%
71%
- Research and Development Expense 1.28 1.28
25% 25%
1%
48 48
12% 12%
25%
- Depreciation and Amortization 5.08 5.08
4% 4%
3%
EBIT (Operating Income) EBIT 43 43
13% 13%
22%
Net Profit 28 28
21% 21%
14%

In millions EUR.

Don't miss a Thing! We will send you all news about Pharmanutra directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Head office Italy
Employees 128
Website www.pharmanutra.it

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today